Decreased physician reimbursement for hormone therapy may reduce over-treatment of prostate cancer
The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer In ...
